Company overview
Acuitas Therapeutics specializes in lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics, including mRNA, siRNA, and DNA payloads. Their clinically validated LNP technology enables approved products like ONPATTRO® for hATTR and COMIRNATY® COVID-19 vaccine, supporting applications in gene editing, RNA interference, and vaccines. The company partners globally with pharma and biotech firms to accelerate drug development without developing proprietary products.
Acuitas Therapeutics is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include lnp delivery, lipid nanoparticles, mrna delivery, sirna therapeutics, gene editing lnp.
Structured facts
- Website
- https://acuitastx.com
- Markets served
- United States & Americas
- Keywords
- lnp delivery, lipid nanoparticles, mrna delivery, sirna therapeutics, gene editing lnp
Products & technologies
Markets served
Company timeline
- — Profile published on NovaPharmaNews
Frequently asked questions
- What LNP delivery capabilities does Acuitas offer?
- Acuitas provides best-in-class LNP systems for nucleic acid therapeutics including mRNA, siRNA, antisense oligonucleotides, and DNA, enabling systemic intravenous delivery for gene editing and modulation, as well as intramuscular vaccine administration.
- What regulatory validations support Acuitas' LNP technology?
- Acuitas' LNP technology is clinically validated in FDA-approved ONPATTRO® (Alnylam) for hATTR amyloidosis and COMIRNATY® (Pfizer-BioNTech) COVID-19 vaccine, with additional programs in clinical development for vaccines and therapeutics.
- What geographies does Acuitas serve and who are key partners?
- Based in Vancouver, Canada, Acuitas partners globally with companies like Bayer for liver-targeted gene editing, Arbor Biotechnologies for rare liver diseases, and Alnylam Pharmaceuticals, supporting international clinical and market advancement.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
